GlassScriptPhysician profile
Cynthia Mayer
NPI 1720061344
$7,292.63
in general payments reported to CMS, 2019-2025
32 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,576 · 2020: $434 · 2021: $1,063 · 2022: $1,286 · 2023: $1,303 · 2024: $574 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,933.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,577.55 | 2019-2025 | |
| Viiv Healthcare Company | $1,090.35 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Janssen Biotech, INC. | $898.49 | 2019-2023 | Symtuza |
| Insmed, INC. | $775.06 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $482.05 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Melinta Therapeutics, LLC | $458.96 | 2019-2024 | Vabomere, Rezzayo, Kimyrsa |
| Astellas Pharma US INC | $351.69 | 2019-2025 | Cresemba |
| Theratechnologies INC. | $283.01 | 2019-2025 | Egrifta, Trogarzo |
| Ferring Pharmaceuticals INC. | $175.00 | 2023 | Rebyota |
| Shionogi INC | $159.60 | 2021-2025 | Fetroja |
| Janssen Scientific Affairs, LLC | $152.64 | 2019-2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $147.32 | 2022-2024 | Livtencity |
| Abbvie INC. | $110.52 | 2020-2025 | |
| Ucb, INC. | $83.09 | 2025 | Bimzelx |
| La Jolla Pharmaceutical Company | $71.92 | 2022-2025 | Xacduro, Zevtera |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $64.02 | 2024-2025 | Hizentra |
| Paratek Pharmaceuticals, INC. | $49.75 | 2019-2023 | Nuzyra |
| Smith+Nephew, INC. | $44.87 | 2019-2025 | Collagenase Santyl |
| Tetraphase Pharmaceuticals, INC. | $44.68 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $39.75 | 2024-2025 | Opsumit, Uptravi |
| Sandoz INC. | $36.77 | 2023-2024 | Hyrimoz |
| Napo Pharmaceuticals INC | $36.50 | 2023 | Mytesi |
| Glaxosmithkline, LLC. | $26.63 | 2025 | Shingrix |
| Kerecis Limited | $26.09 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Hologic Sales and Service, LLC | $25.24 | 2024 | Thinprep 2000 Processor, Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.50 | 2023 | Spevigo |
| Lilly USA, LLC | $20.21 | 2023 | Taltz, Olumiant |
| Grifols USA, LLC | $20.02 | 2025 | Xembify |
| Vbi Vaccine (Delaware) INC. | $18.35 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.